This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.
General Information
Mouse: FVB/N x 129S6/SvEvTac
Expression of the human mutant (A53T) alpha-synuclein protein using the P1 artificial chromosome (PAC).
Endogenous alpha-synuclein: No
Corresponding human genotype: Autosomal dominant mutation in PD patients (PARK1/PARK4)
Transgene insertion: 4 chromosomal insertions
Reference: Kuo 2010
Transgene expression
- 6 weeks-6 months: high (2-8 x) but stable transgene expression is observed in the whole brain and distal colon.
Neurodegeneration
- 11 and 18 months: no evident loss of TH-positive neurons is observed in the SN
Dopamine Homeostasis
- 11 and 18 months: No deficits are observed
Inclusions
- 6-18 months: no alpha-synuclein abnormalities are detected in the brain. Inclusions are observed in the enteric nervous system
Motor Behaviours
- No gross motor symptoms (ataxia, tremor, paralysis) can be observed at any time
- 6-12 months: a reduced latency in the rotarod test indicative of motor impairment is present . Reduced distance travelled is detected in the open field test
- 18 months: increased impairment in rotarod test and reduced distance in the open field test are observed. This later impairment is not due to a reduced exploratory behaviour (increased anxiety is not observed in this model)
Response to L-DOPA treatment
- Not reported
Non motor Behaviours
- Colonic deficits: Reduction in expulsion time is observed at 3-18 months. This reduction is higher in male when compared to female. Reduction of the amount of stool that increases with age is observed (greater at 12 months compared to 6 months).
- Whole-gut transit time: time-dependent increase (3-18 months) of transit time
- Olfaction: no deficits are observed.
- Autonomic dysfunctions: no deficits are observed
Electrophysiology
- Not reported.
Neuroinflammation
- Not reported.
